获得国家自然科学基金青年项目、上海市启明星计划扬帆专项等项目资助。 以第一作者或通讯作者在Signal Transduction and Targeted Therapy、European Journal of Medicinal Chemistry💇♂️、Translational Oncology📟、Cancer Medicine👩🦳👯♂️、Cancer & Metabolism等国际期刊发表多篇原创论文。
【主持科研项目】
1) 上海市科学技术委员会，22YF1433500, 启明星培育（扬帆专项）, 2022-04 至 2025-03，20万元, 主持
2) 国家自然科学青年基，22207084，2023-01至2025-12，30万，主持
【代表性文章】（#第一作者，*通讯作者）
Li, Yaxu; Ran, Qiao; Duan, Qiuhui; Jin, Jiali; Wang, Yanjing; Yu, Lei; Wang, Chaojie; Zhu, Z.; Chen, Xin; Weng, Lingjun; Li, Zan; Wang, Jia; Wu, Qi; Wang, Hui; Tian, Hongling; Song, Sihui; Shan, Zezhi; Zhai, Qiwei; Qin, Huanlong; Chen, Shili; Fang, Lan; Yin, Huiyong; Zhou, Hu; Jiang, Xuejun; Wang, Ping, 7-Dehydrocholesterol dictates ferroptosis sensitivity. Nature 2024, 626, 411-418.
Yu, Lei#; Zhao, Pengcheng#; Sun, Yaoliang#; Zheng, Zening#; Du, Wenhao; Zhang, Lishan; Li, Yaxu; Xie, Longyan; Xu, Shilin; Wang, Ping, Development of a potent benzonitrile-based inhibitor of glutaminyl-peptide cyclotransferase-like protein (QPCTL) with antitumor efficacy. Signal Transduction and Targeted Therapy 2023, 8, 454.
Zhao, Pengcheng, Xie, Longyan, Yu, Lei∗, Wang, Ping∗. Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy. Genes & Diseases, 2023, 11(1):205-217.
Li, Zhiqiang, Gu, Xuemei, Danni Rao, Lu, Meiling, Wen, Jing, Chen, Xinyan, Wang, Hongbing, Cui, Xianghuan, Tang, Wenwen, Xu, Shilin, Wang, Ping∗, Yu, Lei∗, Ge, Xin∗, Luteolin promotes macrophage-mediated phagocytosis by inhibiting CD47 pyroglutamation, Translational Oncology, 2021, 14 (8):101129.
Yu, Lei; Teoh, Shao Thing; Ensink, Elliot Ogrodzinski, Martin P.; Yang, Che; Vazquez, Ana I. Lunt, Sophia Y. ∗; Cysteine catabolism and the serine biosynthesis pathway support pyruvate production during pyruvate kinase knockdown in pancreatic cancer cells，Cancer & Metabolism, 2019, 7:13.
Yu, Lei; Huang, Minhao; Xu, Tianfeng; Tong, Linjiang; Yan, Xiao-e; Zhang, Zhang; Xu, Yong; Yun, Caihong; Xie, Hua∗; Ding, Ke∗; Lu, Xiaoyun∗; A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFR(L858R/T790M) mutant with improved pharmacokinetic properties, European Journal of Medicinal Chemistry, 2016, 126, 1107-1117.
Zhang, Zhang#; Zou, Jian#; Yu, Lei#; Luo, Jinfeng; Li, Yan; Tu, Zhengchao; Ren, Xiaomei; Wei, Hongcheng∗; Song, Liyan∗; Lu, Xiaoyun∗; Ding, Ke∗; YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFR (L858R, T790M)-mutant resistance in vitro and in vivo, Cancer Medicine, 2018, 10.1002/cam4.1392
Lu, X.; Yu , Lei; Zhang, Z.; Ren, X.; Smaill, J.; Ding, Ke∗, Targeting EGFR L858R/T790M and EGFR L858R/T790M/C797S Resistance Mutations in NSCLC: Current Developments in Medicinal Chemistry, Med. Res. Rev. 2018, 38 (5) , 1550-1581. (IF:9.791)
Ogrodzinski, M.P.; Teoh, S.T.; Yu , Lei; Broadwater, D.; Ensink, E.; Lunt, S.Y., Measuring the Nutrient Metabolism of Adherent Cells in Culture, Metabolic Signaling. Methods Mol Biol, Humana Press, New York, NY, 2019, 1862, 37-52.
Yu, Lei; Wang, Zhen; Zhang, Zhang; Ren, Xiaomei; Lu, Xiaoyun∗; Ding, Ke∗; Small-Molecule BET Inhibitors in Clinical and Preclinical Development and Their Therapeutic Potential, Current Topics in Medicinal Chemistry, 2015,15 (8), 776-794.
【专利】
1) 王平; 余蕾; 徐石林; 赵鹏程; 杜文浩; 张利山; 谢龙妍 ; 谷氨酰胺环化酶抑制剂及其应用, 2022-1-30, 中国, 202210114813.8
2) 王平; 余蕾; 徐石林; 赵鹏程; 孙姚良；杜文浩; 张利山; 谢龙妍 ; 谷氨酰胺环化酶抑制剂及其应用, 2023-2-5, 中国, 202310062973.7
3) 王平; 余蕾; 徐石林; 赵鹏程; 孙姚良；杜文浩; 张利山; 谢龙妍；谷氨酰胺环化酶抑制剂及其应用，PCT/CN2023/131599
4) 王平,徐石林,余蕾,孙姚良,安琪,郑泽柠🚯，一种含氮杂环化合物及其应用，2024-5-28, 中国, 202410673223.8
